Soleno Therapeutics (SLNO) Short term Debt (2013 - 2014)
Soleno Therapeutics (SLNO) posted quarterly Short term Debt of $101529.0 for Q4 2014, down 99.27% year-over-year from $14.0 million in Q4 2013, and down 99.27% quarter-over-quarter from $14.0 million in Q4 2013.
Soleno Therapeutics (SLNO) Short term Debt (2013 - 2014) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Short term Debt for 2 consecutive years, with $101529.0 the latest figure, recorded in Q4 2014.
- In Q4 2014, Short term Debt fell 99.27% year-over-year to $101529.0; the TTM figure through Dec 2014 stood at $101529.0 (down 99.27% YoY), while the FY2014 annual figure was $101529.0, down 99.27% from the prior year.
- Short term Debt declined to $101529.0 in Q4 2014 per SLNO's latest filing, from $14.0 million in the prior quarter.
- Across five years, Short term Debt topped out at $14.0 million in Q4 2013 and bottomed at $101529.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 101,529.00 |
| Dec 31, 2013 | 13.99 Mn |